Saturday, November 08, 2014 9:24:45 PM
The FDA just approved Afrezza, an inhaled insulin for both Type 1 and Type 2 diabetics. It will be available for prescription very soon, so will there be a run on it? Here are ten points to keep in mind.
1. The product will be called Afrezza and was developed by the MannKind Corporation.
2. It’s not the first time we’ve heard about inhaled insulin. Exubera, Pfizer’s attempt at inhaled insulin, was never popular because of a possible increase in lung cancer.
3. While we don’t know if there is a connection, there were also more cases of lung cancer in patients taking Afrezza in the clinical trials.
my comment I did not know about the lung cancer.
4. Inhaled insulin will be an expensive medication. How expensive? Don’t know yet.
5. Exubera, the other inhaled insulin, was pulled from the market after 2 years because sales were so low. I never prescribed it. The Exubera device was difficult to use and large. There is reason to believe that it will be different this time. The Afrezza device is small and easy to use.
6. Two other drug companies that were making an inhaled insulin pulled out after the failure of Exubera.
7. Insurance companies may decide to cover Afrezza because the studies of Afrezza show a low risk of hypoglycemia (low blood sugars). Low sugars can lead to substantial cost to insurers so they may embrace Afrezza.
8. Afrezza is a rapid-acting inhaled insulin used prior to meals or within 20 minutes of starting a meal. Remember it is not a substitute for long-acting insulin and must be used in combination with long-acting insulin in patients with type 1 diabetes.
9. Afrezza will have a boxed warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease. So those folks should stay away from it for now.
10. The work is not done. The FDA is requiring 4 post-marketing studies for Afrezza including a look at use in pediatric patients, and a closer look at the risk for lung cancer.
TRADING TNA AND TZA
http://investorshub.advfn.com/TRADING-TNA-AND-TZA-12981/
Recent MNKD News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:05:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:05:34 PM
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- US Index Futures Rise Amid Earnings Season Optimism, Oil Prices Rebound • IH Market News • 08/07/2024 09:49:12 AM
- MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease • GlobeNewswire Inc. • 07/31/2024 10:30:00 AM
- MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 • GlobeNewswire Inc. • 07/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:22:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:19:34 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM